M. Hallak et al., ACTIVATED PROTEIN-C RESISTANCE (FACTOR-V-LEIDEN) ASSOCIATED WITH THROMBOSIS IN PREGNANCY, American journal of obstetrics and gynecology, 176(4), 1997, pp. 889-893
OBJECTIVE: Our purpose was to evaluate activated protein C resistance
phenotype and genotype among patients with thrombosis during pregnancy
and the puerperium. STUDY DESIGN: This observational study was conduc
ted prospectively during a 2-year period (July 1993 to June 1995) in a
preselected population. All patients admitted to our high-risk pregna
ncy unit with a diagnosis of deep vein thrombosis, pulmonary emboli, t
ransient ischemic attack, and cerebrovascular accident during pregnanc
y and the puerperium were included. Prothrombin time, partial thrombop
lastin time, fibrinogen revels, protein C, protein S, antithrombin III
, functional test for activated protein C resistance, and factor V Lei
den mutation by polymerase chain reaction were performed on each patie
nt. RESULTS: Fifteen patients were included. Seven (46.6%) patients we
re positive for activated protein C resistance (factor V Leiden). All
other coagulation studies were negative for all patients. All patients
with activated protein C resistance had a venous thrombotic event, de
ep vein thrombosis, or pulmonary emboli, and only one had a cerebrovas
cular accident on the basis of sagittal sinus thrombosis. Only two of
the activated protein C resistance-negative patients had venous thromb
osis (pulmonary emboli). The remaining six patients had transient isch
emic attacks or cerebrovascular accidents. For the subgroup with venou
s thrombosis during pregnancy and the puerperium, the incidence of act
ivated protein C resistance (factor V Leiden) was 78%. CONCLUSION: Thi
s study demonstrates the incidence of factor V Leiden in a selected po
pulation in whom thrombotic events developed during pregnancy and the
puerperium. This small-scale study provides justification for a large
cohort study that will identify women with factor V Leiden and determi
ne their risk for thrombosis during pregnancy and the puerperium. We b
elieve that factor V Leiden should be evaluated in conjunction with th
rombotic events in the pregnant woman.